
Evolent Health (EVH) Stock Forecast & Price Target
Evolent Health (EVH) Analyst Ratings
Bulls say
Evolent Health is on track to continue its strong financial performance with an estimated 2027 adjusted EBITDA of $151M, supported by signed contracts and strategies to offset potential growth headwinds. Management's conservative reserve load for its Highmark contract is expected to decrease as they gather more data, and they continue to see growth in commercial and Medicare segments. Despite potential challenges, such as slower than expected client signings, Evolent's strong position in the value-based care market makes it a solid investment with long-term growth potential.
Bears say
Evolent Health is facing potential risks associated with the healthcare information technology (HCIT) space, as a significant portion of its spending comes from government programs and may be affected by budget cuts or customer losses. However, with a strong performance in Q2 and a new $300 million oncology contract, the company is expected to see approximately 25% revenue growth in 2027, alleviating concerns about profitability and solidifying demand for its Performance Suite offering. Despite potential uncertainties, the company's business model and improved visibility make its shares appealing for investors.
This aggregate rating is based on analysts' research of Evolent Health and is not a guaranteed prediction by Public.com or investment advice.
Evolent Health (EVH) Analyst Forecast & Price Prediction
Start investing in Evolent Health (EVH)
Order type
Buy in
Order amount
Est. shares
0 shares